Mymetics Corp (MYMX)

[bow-tie]

This study points to a similar mode of action for the two viral proteins, suggesting that anti-viral strategy that targets the viral-induced membrane fusion step can be adopted from HIV-1 to SARS-CoV. Recently the FDA approved Enfuvirtide, a synthetic peptide corresponding to the C-terminal heptad repeat of HIV-1 gp41, as an anti-AIDS agent. Enfuvirtide and C34, another anti HIV-1 peptide, exert their inhibitory activity by binding to a leucine/isoleucine zipper-like sequence in gp41, thus inhibiting a conformational change of gp41 required for its activation. We suggest that peptides corresponding to the C-terminal heptad repeat of the S2 protein may serve as inhibitors for SARS-CoV entry.
https://bmcmicrobiol.biomedcentral.com/articles/10.1186/1471-2180-3-20



PDF) Antiviral properties of two trimeric recombinant gp41 ...
www.researchgate.net/publication/7261736...
Mymetics Corporation, 14, rue de la Colombière, 1260 Nyon, Switzerland, 3. ... or Enfuvirtide) is a synthetic pept ide corre-sponding to 36 conserved residues within C-HR. This pep-


Note: Rgp41A can interact with soluble monomeric gp120

https://www.researchgate.net/publication/7261736_Antiviral_properties_of_two_trimeric_recombinant_gp41_proteins